Idorsia-expands Quviiq into China as Simcere receives NDA approval

23 June 2025

Swiss drugmaker Idorsia (SIX: IDIA) today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling.

In addition, Idorsia – whose shares rose 7.6% to 2.04 francs on the news - has reached an agreement with Simcere to update the terms of the licensing agreement for Quviviq in China.

The global insomnia market was valued at $5.34 billion in 2024 and is projected to reach $6.78 billion by 2033, with a compound annual growth rate (CAGR) of 2.55% from 2025 to 2033, according to IMARC Group. North America currently holds a dominant position in the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK